Saturday, November 14, 2026Published by SAM & FDPS · Our work → · Submit an op-ed →
Explainer · Psychedelics

Psychedelics, explained: the evidence, the harms and the push to legalize

Psilocybin, MDMA, LSD and ibogaine are being sold to the public as medicine before any of them has passed the test every other medicine has to pass. The one that reached the FDA was rejected. The largest fair comparison found psychedelic therapy no better than antidepressants. And teen use disorder, poison center calls and storefront sales are rising in the states that went first.

41%

rise in hallucinogen use disorder among 12 to 17 year olds in one year, 59,000 to 83,000

Source: NSDUH 2024

10 to 1

FDA advisers voted that MDMA therapy’s benefits did not outweigh its risks

Source: FDA advisory committee, 2024

3x

psilocybin poison center cases among adolescents more than tripled from 2018 to 2022

Source: J. Adolescent Health

0

classic psychedelics approved by the FDA to treat any condition

Source: SAMHSA, 2026

56%

of Massachusetts voters rejected psychedelic legalization in 2024

Source: Ballotpedia

What are psychedelics?

Psychedelics, also called hallucinogens, are mind-altering drugs from plants, fungi or a lab that change perception, mood and thinking. The ones in the policy debate are psilocybin (magic mushrooms), LSD, MDMA (ecstasy, generic name midomafetamine), DMT and mescaline, and ibogaine, a compound from an African shrub promoted as an addiction treatment. All of them are Schedule I controlled substances under federal law, which means the government has determined they have a high potential for abuse and no accepted medical use.

Ketamine is often grouped with them but is a different case. It is an anesthetic, not a classic psychedelic, and esketamine, a ketamine-derived nasal spray, was approved for depression in 2019 after going through the full FDA process. That is the standard the psychedelics industry is now asking to shortcut.

Over the past five years the drugs have been rebranded from counterculture to medicine: for depression, PTSD, anxiety, addiction and end-of-life distress. The claims have outrun the evidence. No classic psychedelic has FDA approval for any indication, the one that reached a decision was turned down, and the largest head-to-head analysis to date found psychedelic therapy no better than ordinary antidepressants once the trials’ blinding problems were accounted for. Meanwhile, teen use disorder, poison center calls and unregulated storefront sales are climbing.

Are psychedelics medicine? What the FDA has and has not approved

None of them, so far. The only psychedelic to reach an FDA decision was Lykos Therapeutics’ MDMA-assisted therapy for PTSD. In June 2024 an FDA advisory committee voted 10 to 1 that the benefits did not outweigh the risks and 9 to 2 that effectiveness had not been shown. That August the agency rejected the application and asked for another Phase 3 trial.

The FDA’s rejection letter, made public in 2025, is the most detailed federal assessment of a psychedelic trial program yet written. It found “substantial concerns about the reliability of the safety data,” unreported adverse events at at least two trial sites, no laboratory data from the Phase 3 studies, and no proof the effect lasted beyond 18 weeks. About 40 percent of participants had used MDMA before, which the agency said raised “selection bias” and “functional unblinding.” It recommended “an independent third-party data audit of all study records and reports, including the recordings of the treatment sessions.” Lykos was spun out of the nonprofit MAPS; papers from its earlier trials had been retracted for ethical violations, including an alleged sexual assault of a participant by a trial therapist.

The politics have moved faster than the science. Executive Order 14401, signed April 18, 2026, directs the FDA to give priority review vouchers to psychedelics with breakthrough designation, cutting review from 10 to 12 months to as little as one to two, orders the Attorney General to move on rescheduling once Phase 3 trials wrap, and tells the FDA and DEA to open a Right to Try pathway for ibogaine. The FDA has since issued vouchers for psilocybin for treatment-resistant depression, psilocybin for major depression and methylone for PTSD. The agency’s own hearing notice is careful about what that means: “Neither national priority voucher issuance nor Breakthrough Therapy designation constitutes an FDA determination of safety or effectiveness.”

A 2026 SAMHSA paper put it plainly: “The data to date does not establish efficacy at large,” and “does not yet establish optimal dosing, frequency of administration, or long-term trajectories.” It then told state mental health agencies to build credentialing and safety systems anyway, before any approval. The American Psychiatric Association said in 2022 there is “inadequate scientific evidence for endorsing the use of psychedelics to treat any psychiatric disorder,” and the Institute for Clinical and Economic Review rated the MDMA evidence “insufficient” in 2024.

The bottom line

Vouchers, breakthrough labels and executive orders change the speed of review. They do not change what the trials found. Every psychedelic that has been put in front of the FDA’s advisers has failed.

The evidence problem: small trials, unblinded patients, missing data

Psychedelic trials have a structural flaw that most drug trials do not: patients can tell whether they got the drug. A placebo does not make the walls breathe. Once a participant knows which arm they are in, expectation does part of the work, and a trial that looks double-blind on paper is not. Researchers call this functional unblinding, and the FDA named it as a central problem in the Lykos letter.

When a team from UCLA, Imperial College London and UCSF corrected for it, the advantage disappeared. Comparing eight psychedelic trials with about 550 participants against 16 antidepressant trials with nearly 9,800, they found that “PAT was no more effective than open-label tAD treatment,” a result that “presents a sobering viewpoint on the treatment’s potential.” Co-author Balázs Szigeti of UCSF told his university: “What I wanted to show is that even if you compare psychedelics to open-label antidepressants, psychedelics are still much better. Unfortunately, what we got is the opposite result, that they are the same.”

The rest of the literature is thin. A 2024 review of nearly 200 published psilocybin studies found that almost half had no control group, the median study had 22 participants, of whom 18 took the drug, and nearly 40 percent relied on self-reported questionnaires for their primary outcome, according to a summary in the Colorado Springs Gazette. SAMHSA notes trial samples of “30 to 250 participants” and benefits unproven beyond six to twelve months. Even the most favorable recent LSD work, a June 2026 Neuropsychopharmacology study of healthy volunteers, “does not demonstrate that LSD treats anxiety or depression,” as its own authors acknowledge.

Psychedelic harms: addiction, poisonings, psychosis

Teenagers. The National Survey on Drug Use and Health found hallucinogen use disorder among 12 to 17 year olds rose 41 percent between 2023 and 2024, from 59,000 to 83,000. With 405,000 teens using a hallucinogen that year, roughly one in five who used met the criteria for a use disorder. A 2024 NSDUH analysis found people who used marijuana in the past year were 12.1 times more likely to have used psilocybin.

Poison centers. University of Virginia researchers counted 4,055 psilocybin exposures among 13 to 25 year olds reported to U.S. poison centers from 2013 to 2022. Cases were flat through 2018, then climbed: by 2022 they had more than tripled among adolescents and more than doubled among young adults, and about three in four required medical attention. A 2025 analysis from the University of Colorado found psilocybin calls involving children up 723 percent from 2019 to 2023, according to FDPS’s psychedelics one-pager.

The trip itself. In survey research cited by FDPS, 39 percent of psilocybin users rated the experience among the five most challenging of their lives and 11 percent said they put themselves or others at risk of physical harm. A former Alaska Airlines pilot who tried to shut down a passenger jet’s engines in flight in 2023 had taken psilocybin about 48 hours earlier. Hallucinogen persisting perception disorder can return months or years after use, bringing visual disturbances, disorganized thinking and paranoia to a sober person.

Psychosis and the heart. Psychedelics are contraindicated for people with a personal or family history of psychosis, and screening is one of the things state storefront programs do not reliably do. Luke Niforatos of FDPS told Colorado Public Radio that a JAMA study found psilocybin users 21 times more likely to develop schizophrenia than the general public. Ibogaine carries documented cardiac deaths and no FDA trial. Repeated LSD exposure, including microdosing, may be associated with valvular heart disease through the same serotonin receptor that pulled fenfluramine off the market.

At the FDA’s September 2026 hearing, Susan Taymor Sagy of the Coalition for Psychedelic Safety and Education told the agency: “My 21-year-old Shira died following psychedelic use.” She said she later met other mothers who lost adult children the same way and found “very little credible, accessible information” about the risks.

Oregon has run psilocybin “service centers” since 2023 with no FDA approval, no prescription and no diagnosis required. Colorado decriminalized personal possession under Proposition 122 in 2022 and licenses “healing centers,” which state law calls Natural Medicine Health Centers. Niforatos calls that name “a total misnomer. No scientists have cleared these products to be medicine. There’s no dosage.” New Mexico created a medical psilocybin program by statute in 2025, New Jersey funded a hospital pilot in 2026, and Texas has put $50 million of state money into ibogaine research.

Voters are less enthusiastic than legislators. Massachusetts rejected Question 4, which would have legalized psilocybin, DMT, mescaline and ibogaine, by 56 percent in November 2024. Twenty months later the state House approved a five-year pilot program anyway, tucked into an economic development package and passed 148 to 2 without a floor speech.

Where the drugs are decriminalized, they end up in stores. In October 2026 police, the DEA and the sheriff raided seven Colorado Springs smoke shops and liquor stores, seizing THC, psilocybin and 7-OH; one had a 16-year-old alone behind the counter. Denver pulled psychedelic chocolate bars from six stores earlier in the year after some tested positive for undisclosed synthetic tryptamines.

The psychedelics industry: who profits

Christian Angermayer, the financier who founded Compass Pathways and ATAI Life Sciences, said it himself in 2026: “Psychedelics needed an evangelist ten years ago. Now it is all about commercialization.” He described the addressable markets as “almost limitless” and “massive financial upside”; the two companies have raised more than $1.5 billion and both trade on Nasdaq.

An October 2025 investigation by Psymposia and Truthdig documented how the Psychedelic Science Funders Collective, a group of wealthy donors, ran “a strategic campaign to shape public perception in favor of Lykos Therapeutics’ failed MDMA-assisted therapy application and demonize its critics,” and positioned veterans groups as an “insurance policy” and “bulwark against backlash.” Its own 2021 planning document explained why: “Tying a policy reform effort to human stories from populations who are either highly sympathetic or highly relatable is one of the most effective ways to create a sense of urgency.”

The money was audible at the FDA’s hearing. One investor said disclosing all of his financial ties “would take me longer than my two minutes”; a drug supplier’s CEO said “Everything I’m about to say advantages my business.” Kevin Sabet of FDPS, who said he was “one of the few here without a financial interest,” asked for the ordinary standard: “Psychedelics should earn approval the way any other class of drug does: through science and trials, not politics or podcasters.”

What critics are asking for

Not a research ban. FDPS, SAM and the parents at the FDA hearing support rigorous controlled trials and FDA approval on the same standard as every other drug, with safety monitoring and credentialing built before approval rather than after. What they oppose is approval on a political timeline, medicine by ballot measure, storefront “healing centers” with no diagnosis or prescription, and an industry writing its own rules. FDPS’s full position: Psychedelics policy.

Psychedelics FAQ

Are psychedelics legal in the United States?

Psilocybin, LSD, MDMA, DMT, mescaline and ibogaine are Schedule I controlled substances under federal law. Oregon licenses psilocybin service centers and Colorado has decriminalized personal possession and licenses healing centers under state law, but federal law has not changed and no psychedelic is sold legally in a store anywhere in the country. Several cities have made enforcement a low priority. Massachusetts voters rejected legalization in 2024.

Has the FDA approved any psychedelic?

No classic psychedelic is FDA-approved to treat any condition. The FDA rejected Lykos Therapeutics’ MDMA-assisted therapy for PTSD in 2024 after its advisers voted 10 to 1 against it, and asked for another Phase 3 trial. Esketamine, a ketamine-derived nasal spray, was approved for depression in 2019 through the normal process, but it is not a classic psychedelic. Priority review vouchers issued in 2026 speed up review; the FDA says they are not a finding of safety or effectiveness.

Do psychedelics cure depression or PTSD?

The trials have not shown that. When researchers compared psychedelic therapy trials with antidepressant trials under equal blinding conditions, psychedelic therapy was no more effective. Most psychedelic studies are small, many have no control group, and participants usually know whether they received the drug, which inflates results. SAMHSA concluded in 2026 that the data do not establish efficacy, dosing or long-term outcomes.

Are psychedelics addictive?

Classic psychedelics do not produce the physical dependence of opioids, but hallucinogen use disorder is a recognized diagnosis, and it is rising. Among 12 to 17 year olds it increased 41 percent in a single year, from 59,000 to 83,000 in 2024, which means about one in five teens who used a hallucinogen met the criteria.

What is a bad trip, and how common is it?

A frightening or disorienting psychedelic experience. In survey research, 39 percent of psilocybin users rated the experience among the five most challenging of their lives and 11 percent said they put themselves or others at risk of physical harm. Psilocybin poison center cases among adolescents more than tripled between 2018 and 2022, and about three in four required medical attention.

What is ibogaine?

A Schedule I hallucinogen derived from an African shrub, promoted as a treatment for opioid addiction. It has documented cardiac risks and has been linked to deaths in unregulated clinics abroad. It is in no FDA trial, yet it is a focus of the April 2026 executive order and of a $50 million state research program in Texas.

Does The Drug Report oppose psychedelic research?

No. The position of FDPS and SAM, which publish The Drug Report, is that psychedelics should go through the same trials and the same FDA approval standard as any other drug, with safeguards built first. They oppose approval on a political timeline, legalization by ballot measure or statute, and storefront sales with no diagnosis, prescription or federal oversight.

Latest psychedelics coverage

All psychedelics coverage: The Drug Report’s Psychedelics section. Related explainers: Marijuana, Kratom and 7-OH and Hemp-derived THC.

This explainer is kept current as the FDA process, state law and the research change. Corrections and tips: [email protected].

Scroll to Top